Continuing review and study closure at Capella: what the board expects after approval

What does the approval letter commit me to?

Capella's Policy 3.03.01 lists the post-approval duties in one place. Researchers must adhere to the approved protocol, "obtain approval from the IRB before modifying their approved research procedures, sites, or forms," report unanticipated problems and adverse events promptly (the policy states the window), maintain CITI currency, "cease performance of research and stop all contact with participants on the expiration date of the IRB approval," and "maintain all research materials for seven years after completion of a study." The SOPs add a duty to "abide by all the determinations of Capella University's IRB" and to cooperate with continuing review, monitoring, and audit, "providing all information requested by the IRB in a timely fashion."

Read the letter itself for three things: the level at which the study was approved (exempt, expedited, or full board), the expiration date if there is one, and any conditions or instructions specific to your study. Capella's SOPs note the IRB "determines the review interval on a case-by-case basis," so the letter, not a general rule, governs your calendar. Any requirement written in the letter is part of the approval.

Which studies need continuing review at Capella?

The federal baseline is 45 CFR 46.109(e): an IRB conducts continuing review of research that required the convened board at intervals matched to the level of risk, "not less than once per year," except as described in 46.109(f). Under 46.109(f)(1), "unless an IRB determines otherwise," continuing review is not required for research eligible for expedited review, or for research "that has progressed to the point that it involves only" data analysis, including analysis of identifiable private information.

Capella's practice sits inside that. Its doctoral-support FAQ on expiring approval says that studies "approved as exempt from full review do not have expiration dates and therefore are not subject to these renewal requirements," and describes a continuing-review path for studies still collecting data. Its SOPs describe continuing review for studies at the expedited and full-board levels and say review interval is set case by case. The operative instruction is the one in your letter: if it states an expiration date, you are on the continuing-review calendar until the study is closed. If you are unsure whether your expedited approval carries a date, ask the IRB Office before you assume.

How does continuing review work in IRBManager?

Capella's FAQ says IRBManager begins sending expiration notices automatically ahead of the date. When one arrives, you have three paths, and silence is the worst of them.

What the form asks for is what the regulation contemplates: the status of the study, how many have been enrolled, whether anything unanticipated happened, whether anyone withdrew or complained, what modifications have been approved since the last review, and whether the consent form in use is the approved one. Prepare it from your records rather than from memory, and attach the current stamped versions of the documents you are using. Capella's SOPs say continuing review is "a review of the full study, not simply a change to it," and warn that if a reviewer finds "study procedures which could subject research participants to increased risk," the study can be revised or referred to full review even if it was originally expedited.

One calendar fact that surprises people: a modification does not reset the clock. Capella's SOPs state that review of a modification "ordinarily does not alter the date by which continuing review must occur," and our piece on changing an approved study at Capella covers why the two tracks stay separate.

What happens if approval lapses?

Capella's SOPs are precise: approval "is considered to have lapsed at midnight on the last day of the approval period." Federal regulations "do not permit the granting of grace periods," and if continuing review has not been completed by the end of the approval period, research activities "must stop" — recruitment, consent, data collection, and participant interaction — unless the IRB finds it is in the best interests of currently enrolled participants to continue, a finding the SOPs describe as usually applicable only in biomedical research. "Enrollment of new participants cannot occur after the expiration of IRB approval." And the consequence the board cares about most for a doctoral study: "failure to maintain current approval may disqualify research data," and continuing to work during a lapse "may also result in corrective actions."

Capella's SOPs also tie activity to registration: doctoral researchers may not recruit or collect data, and "may not submit modification or continuing review requests," unless registered in the dissertation or capstone course. If a quarter of inactivity is coming, plan continuing review and any participant communication around it before the break begins, not after.

If you find yourself past the date, stop, write down exactly what was done after expiration, and contact the IRB Office and your mentor the same day. The honest report is the recoverable position.

What do I report between reviews?

• Unanticipated problems and adverse events — promptly; Capella's policy and SOPs both state the reporting window. The policy defines an unanticipated problem as an event "that the researcher did not predict in advance, that is related or potentially related to the research, and that may suggest participants or others are at greater risk of harm than originally assessed." In an emergency the policy's order is: stop, assist the participant, report.
• Participant complaints or concerns — the SOPs route these to a compliance specialist for prompt handling.
• Deviations from the approved protocol — including anything done under a one-time exception, which is requested in writing beforehand.
• Changes in a conflict of interest — reviewed as a modification.
• Anything the letter told you to report.

The SOPs' list of non-compliance examples reads like the inverse of this list: research after lapse, changes without approval, failure to report concerns or adverse events, undisclosed conflicts, undue influence in recruitment. The board's oversight after approval is mostly a matter of you telling it things on time.

How is a study closed, and what changes after closure?

Capella's SOPs call completion "a change in activity that must be reported to the IRB." Closure occurs when the researcher has finished data collection and analysis and "acknowledges that he or she will no longer contact participants, enroll participants, collect further data for the study, or engage in analysis of identifiable participant data." The researcher submits the IRB Study Closure Form; the FAQ describes closing by email to the IRB Office as well. The IRB may also close a study itself when approval has expired without a continuing-review submission, or when the researcher withdraws or is discontinued from the university, and will notify you either way.

After closure: no participant contact, no further collection, no analysis of identifiable data. Writing up de-identified findings continues. Your records — consent forms, data, communications with participants, and anything that could link a participant to the study — are kept and destroyed on the schedule in your approved data plan and Capella's retention policy. Capella's SOPs note that IRB monitoring ordinarily concludes at graduation or withdrawal, with an exception for serious allegations or adverse-event reports, which can be followed up afterward.

What to do next

If your approval letter has a date on it and the work is still under way, put the date where you will see it, and gather the continuing-review facts now. If you would rather have the whole post-approval track handled — the Continuing Review form, any modifications, the reports, and the closure — that is within what we do; the engagement runs from the determination through every reply to the board until approval, and it can run through closure. How it works explains the arrangement and the FAQ answers the usual questions. Send us the approval letter and the approved application for a free review; we will tell you what the board will want at renewal and what it will want at closure. The step-by-step Capella IRB process shows where this stage sits in the whole sequence.